Update on NUTROPIN AQ® (SOMATROPIN) NuSpin® Supply

Information Current as of February 2024

Genentech is expecting a supply shortage for Nutropin AQ® (somatropin) NuSpin® 5 mg, 10 mg, and 20 mg beginning August 2023 in the United States. The shortage is driven by a significant and sustained increase in demand due to fluctuations in supply across several growth hormone manufacturers. Our teams have been working to make Nutropin AQ® (somatropin) NuSpin® available as quickly and widely as possible. However due to very high demand we still expect a shortage.

Genentech anticipates these issues will persist for the next several months, with potential return to supply stability in the first half of 2024. We are committed to proactive and timely communication as the situation evolves, and Nutropin AQ® (somatropin) NuSpin® supply becomes more readily available.

We do not recommend treatment-naive patients start on Nutropin AQ® (somatropin) NuSpin® given the shortage situation. We encourage patients and their caregivers to have a discussion with their doctors on the best alternative treatment options, including a potential change in the formulation prescribed or switching to alternative growth hormones, all subject to their doctor’s clinical judgment and market availability.

We understand that this situation may be stressful and has a critical impact on our patients, families and providers. We are working through the options available to address this situation as quickly as possible.

Prescribing Nutropin AQ® (somatropin) NuSpin®

We anticipate patients and HCPs may experience delays in refilling prescriptions and do understand the stress that this situation may cause. We encourage Patients and HCPs to have discussions regarding a potential change in the formulation prescribed as different Nutropin AQ® (somatropin) NuSpin® formulations may be available intermittently depending on the patient’s specialty pharmacy. Nutropin AQ® (somatropin) NuSpin® formulations are available in a 5 mg/2 ml (clear device), 10 mg/2 mL (green device) and 20 mg/2 ml (blue device).

Please note concentration differences when evaluating a change in formulation and refer to Nutropin AQ® (somatropin) NuSpin® Prescribing Information for additional information. Additionally, switching to alternative growth hormones could also be considered based on the HCP’s clinical judgment and market availability.

If you are a patient or healthcare professional seeking information on Nutropin AQ please contact out Patient Resource Center at (877-436-3683).

If you suspect that you have received an illegitimate medicine, contact Genentech's Product Complaint Hotline at 1-800-334-0290, and file a report with the FDA’s Office of Criminal Investigations (OCI): call 1-800-551-3989 or visit www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm

For the most up-to-date information on product availability for Nutropin AQ, hospitals and practices should contact their authorized distributors. Distributors can click here for the latest information on Nutropin AQ® supply.